|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have characterized regulation of type-1 plasminogen activator inhibitor (PAI-1) gene expression by phorbol 12-myristate 13-acetate (PMA) and the cAMP-inducing agent forskolin in the human breast carcinoma cell line MCF-7.
|
8119299 |
1994 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that TPA-responsive in vitro invasive properties that are probably associated with PAI-1 expression may co-vary with progression from hormone-dependent to -independent breast cancer.
|
9568638 |
1998 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, few data about the mRNA expression of ER, PR, pS2, and PAI-1 in breast cancer are available, which is mostly due to the limitations of conventional techniques for mRNA analysis.
|
10389938 |
1999 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.
|
10517346 |
1999 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied the expression of uPA, urokinase plasminogen activator receptor (uPAR)- and plasminogen activator inhibitor type-1 (PAI-1) in human breast carcinomas and their bone metastases, using in situ hybridisation.
|
10930085 |
2000 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.
|
10961693 |
2000 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, a full-length human HER-2/neu cDNA was introduced into five human breast cancer cell lines to define the effects of HER-2/neu overexpression on uPA and PAI-1 expression.
|
11489825 |
2001 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent evidence confirms the independent prognostic value of VEGF, UPA and PAI-1 in women with early breast cancer and suggests that such parameters may have a role in selecting systemic therapy.
|
11759180 |
2001 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients.
|
12023852 |
2002 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to verify if the different polymorphisms in the PAI-1 promoter are also associated with alterations in the intracellular accumulation of uPA-PAI complexes in human breast cancer.
|
12065877 |
2002 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.
|
12530032 |
2003 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stromal cells also contribute to breast cancer growth and metastasis through the production of extracellular matrix (ECM) modifiers such as urokinase type plasminogen activator (uPA), its receptor (uPAR), its inhibitors (PAI-1 and PAI-2), matrix metalloproteinases (MMPs), and growth factors, including the fibroblast and insulin-like growth factors (FGF's and IGF's).
|
12574821 |
2003 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It confirms that TIMP-1 may be useful as a prognostic marker in combination with uPA/PAI-1 and adds substantial positive information on the use of TIMP-1 as a prognostic marker in breast cancer.
|
15073104 |
2004 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prompted by the conspicuous absence of studies examining the role of the ME in breast cancer progression, we studied the expression of the urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor type-1 (PAI-1) in MEs of 60 DCIS samples.
|
15226768 |
2004 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA.
|
15907980 |
2006 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
|
17062678 |
2006 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, local factors, such as CTGF and genomic amplification, seem to be more important than germ line genetic variation in influencing PAI1 expression and its untoward effects in breast cancer.
|
17119035 |
2006 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to evaluate the association between PAI-1 gene 4G / 5G polymorphism and breast cancer.
|
17309181 |
2007 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Breast carcinoma MDA MB 231 cells are known for both having important metastatic capacities and expressing high levels of PAI-1.
|
17509745 |
2007 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed at studying the -675 4G/5G polymorphism of the PAI-1 gene and uPA, PAI-1, and cyclooxygenase-2 (COX-2) immunohistochemical expression in a series of breast cancer cases.
|
17580278 |
2007 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most importantly, we identified the -675 4G/5G SNP in the PAI-1 gene as a promising prognostic biomarker for breast cancer.
|
17616807 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Urokinase plasminogen activator (uPA) and its main inhibitor, plasminogen activator inhibitor type-1 (PAI-1) determined in tumor tissue by means of enzyme-linked immunosorbent assay (ELISA) can discriminate patients with primary breast cancer at high risk vs low risk for recurrence.
|
17709314 |
2007 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, correlations between uPA/PAI-1 mRNA and protein in the breast cancer samples were found to be distinctly weaker or not significant.
|
18204793 |
2008 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, uPA and PAI-1 provide the unique opportunity to allow validated and clinically relevant risk assessment of breast cancer patients, over and above that provided by established risk factors.
|
18429492 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer.
|
18465330 |
2008 |